Study Protocol for a Multicenter Phase 1 Clinical Trial Evaluating Tucatinib, Trastuzumab, and Capecitabine Combined with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR) - Quiz - MDSpire

Study Protocol for a Multicenter Phase 1 Clinical Trial Evaluating Tucatinib, Trastuzumab, and Capecitabine Combined with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR)

  • By

  • Zouina Sarfraz

  • Ahmad Ozair

  • Mainak Bardhan

  • Amy K. Starosciak

  • Dilanis C. Perche

  • Lydia C. Hodgson

  • Yazmin Odia

  • Minesh P. Mehta

  • Rupesh Kotecha

  • Michael W. McDermott

  • Arun Maharaj

  • Ana Cristina Sandoval Leon

  • Reshma Mahtani

  • Manmeet S. Ahluwalia

  • December 4, 2025

  • 0 min

Share

Original Source(s)

Study Protocol for a Multicenter Phase 1 Clinical Trial Evaluating Tucatinib, Trastuzumab, and Capecitabine Combined with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR)

  • by Zouina Sarfraz, Ahmad Ozair, Mainak Bardhan, Amy K. Starosciak, Dilanis C. Perche, Lydia C. Hodgson, Yazmin Odia, Minesh P. Mehta, Rupesh Kotecha, Michael W. McDermott, Arun Maharaj, Ana Cristina Sandoval Leon, Reshma Mahtani, Manmeet S. Ahluwalia

  • December 4, 2025

Related Content

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer